New CEO is just the tonic for the MDC

THE Cheshire-based Medicines Discovery Catapult has appointed its first chief executive – Chris Molloy.

Molloy has more than 25 years’ experience in the international life science industry, and will lead the MDC in developing new approaches for the discovery and early development of new medicines.  

Currently CEO at the RSA Group, Molloy has significant senior level experience across pharmaceuticals, biotechnology, informatics and start-up sectors.

He will join MDC in November and work with the MDC’s board to develop and implement the Catapult’s initial five year business plan, which will be agreed with Innovate UK at the end of this year.  

The MDC is based at Alderley Park – a hub of life science expertise.  The Catapult, the first for drug R&D in the UK, is chaired by life sciences businessman and academic, Professor Graham Boulnois.

Boulnois said: “We are delighted to bring Chris on board as we start our exciting journey at the Medicines Discovery Catapult. 

“Chris’ experience of leading companies operating in life sciences combined with his in-depth knowledge of drug discovery will be of tremendous value to the company.”  

Molloy said, “I am very much looking forward to building and leading the team at the Medicines Discovery Catapult.

“The UK has a wealth of talent and capability in drug R&D, and a strong tradition in the sector. Particularly at this time of national change, the UK has the opportunity and responsibility to harness these resources, which will enhance the flow of new drugs to a global market.

“The Catapult will be a nexus for great drug R&D science, technology and informatics: delivering multidisciplinary approaches to meet this challenge.

“Fundamental to its mission will be the fact that great people make great R&D, something I have seen throughout my career and recently in advising RSA’s global clients.”